Literature DB >> 21565677

Ovarian hypertension: polycystic ovary syndrome.

Rhonda Bentley-Lewis1, Ellen Seely, Andrea Dunaif.   

Abstract

Hypertension is a significant contributor to the risk for cardiovascular disease. The increased prevalence of hypertension in women with polycystic ovary syndrome (PCOS) may contribute to the increased risk of cardiovascular disease in these women. Whether hypertension is associated with PCOS independent of obesity remains controversial. Nevertheless, detection and subsequent treatment of hypertension in this population should decrease the adverse sequelae from hypertensive cardiovascular disease. Treatment of risk factors inherent to PCOS, such as hyperandrogenism, insulin resistance, and obesity, may minimize the risk not only for the development of hypertension but also for incident cardiovascular disease independent of hypertension.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21565677      PMCID: PMC3253555          DOI: 10.1016/j.ecl.2011.01.009

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  116 in total

1.  Spironolactone therapy for hirsutism in a hyperandrogenic woman.

Authors:  K P Ober; J F Hennessy
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

2.  Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells.

Authors:  J K Wickenheisser; P G Quinn; V L Nelson; R S Legro; J F Strauss; J M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

3.  Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.

Authors:  Mei-Jou Chen; Wei-Shiung Yang; Jehn-Hsiahn Yang; Chi-Ling Chen; Hong-Nerng Ho; Yu-Shih Yang
Journal:  Hypertension       Date:  2007-03-26       Impact factor: 10.190

4.  Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity--but not a PCOS-associated phenomenon.

Authors:  I J Ketel; C D Stehouwer; R M Henry; E H Serné; P Hompes; R Homburg; Y M Smulders; C B Lambalk
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

5.  Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Joachim Spranger; Matthias Möhlig; Uta Wegewitz; Michael Ristow; Andreas F H Pfeiffer; Thilo Schill; Hans W Schlösser; Georg Brabant; Christof Schöfl
Journal:  Clin Endocrinol (Oxf)       Date:  2004-12       Impact factor: 3.478

6.  Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

Authors:  H F Escobar-Morreale; G Villuendas; J I Botella-Carretero; J Sancho; J L San Millán
Journal:  Diabetologia       Date:  2003-05-09       Impact factor: 10.122

7.  Induction of ovulation and pregnancy with pulsatile luteinizing hormone releasing factor: dosage and mode of delivery.

Authors:  R L Reid; G R Leopold; S S Yen
Journal:  Fertil Steril       Date:  1981-11       Impact factor: 7.329

8.  Association between salt sensitivity and insulin concentrations in patients with hypertension.

Authors:  I Zavaroni; P Coruzzi; L Bonini; G L Mossini; L Musiari; P Gasparini; M Fantuzzi; G M Reaven
Journal:  Am J Hypertens       Date:  1995-08       Impact factor: 2.689

9.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.

Authors:  M Ashraf Ganie; M L Khurana; M Eunice; N Gupta; M Gulati; S N Dwivedi; A C Ammini
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

10.  Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome.

Authors:  Maria M Orbetzova; Rositza G Shigarminova; Gencho G Genchev; Boika A Milcheva; Lachezar B Lozanov; Nikolay S Genov; Sabina Z Zacharieva
Journal:  Folia Med (Plovdiv)       Date:  2003
View more
  25 in total

1.  Hyperandrogenemia reduces endothelium-derived hyperpolarizing factor-mediated relaxation in mesenteric artery of female rats.

Authors:  Jay S Mishra; Amar S More; Gary D V Hankins; Sathish Kumar
Journal:  Biol Reprod       Date:  2017-06-01       Impact factor: 4.285

2.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 3.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

4.  Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome.

Authors:  Ratneev Kaur; Tajinder Kaur; Anupam Kaur
Journal:  J Assist Reprod Genet       Date:  2018-03-22       Impact factor: 3.412

Review 5.  Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity.

Authors:  Manuel Luque-Ramírez; Héctor F Escobar-Morreale
Journal:  Curr Hypertens Rep       Date:  2014-12       Impact factor: 5.369

6.  Regulation of Blood Pressure, Appetite, and Glucose by CNS Melanocortin System in Hyperandrogenemic Female SHR.

Authors:  Jussara M do Carmo; Alexandre A da Silva; Sydney P Moak; Haley J Houghton; Andrew Smith; John E Hall
Journal:  Am J Hypertens       Date:  2015-11-18       Impact factor: 2.689

7.  Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.

Authors:  Vanessa Hoang; Jiangjiang Bi; Sheba M Mohankumar; Arpita K Vyas
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 8.  Hypertension in Women Across the Lifespan.

Authors:  Lama Ghazi; Natalie A Bello
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.967

9.  Weight loss for women with and without polycystic ovary syndrome following a very low-calorie diet in a community-based setting with trained facilitators for 12 weeks.

Authors:  Efsevia A Nikokavoura; Kelly L Johnston; John Broom; Wendy L Wrieden; Catherine Rolland
Journal:  Diabetes Metab Syndr Obes       Date:  2015-10-14       Impact factor: 3.168

Review 10.  Epidemiology, diagnosis, and management of polycystic ovary syndrome.

Authors:  Susan M Sirmans; Kristen A Pate
Journal:  Clin Epidemiol       Date:  2013-12-18       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.